Victory Capital Management Inc. Has $27.43 Million Holdings in Zoetis Inc. $ZTS

Victory Capital Management Inc. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 88.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 187,489 shares of the company’s stock after selling 1,382,837 shares during the period. Victory Capital Management Inc.’s holdings in Zoetis were worth $27,433,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after acquiring an additional 419,777 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares during the last quarter. Norges Bank bought a new position in shares of Zoetis during the 2nd quarter valued at $809,491,000. Brown Advisory Inc. lifted its stake in shares of Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after purchasing an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after purchasing an additional 550,859 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.6%

ZTS stock opened at $121.54 on Monday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The business’s 50 day moving average is $126.06 and its 200-day moving average is $132.88. The firm has a market cap of $51.31 billion, a P/E ratio of 20.19, a P/E/G ratio of 1.85 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the business posted $1.40 earnings per share. The business’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. HSBC set a $140.00 target price on Zoetis in a report on Wednesday, December 10th. Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.